# BioMarin Pharmaceutical Inc (BMRN) FY2026 Q2 P&L / Income Statement

- Company: BioMarin Pharmaceutical Inc (BMRN)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-06, accession number 0001048477-26-000016
- Page: https://plicit.ai/financials/bmrn/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/bmrn-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (Schedule of Total Revenues and Disaggregates Net Product Revenues by Product). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 989,708,000 US dollars
- **Cost of sales**: 202,795,000 US dollars
- **Gross profit (calculated)**: 786,913,000 US dollars
- **Operating expenses (calculated)**: 675,993,000 US dollars
- **INCOME FROM OPERATIONS**: 110,920,000 US dollars
- **Other income (expense), net (calculated)**: negative 49,536,000 US dollars
- **INCOME BEFORE INCOME TAXES**: 61,384,000 US dollars
- **Provision for income taxes**: 16,622,000 US dollars
- **NET INCOME**: 44,762,000 US dollars
- **Royalty and other revenues**: 5,315,000 US dollars
- **VOXZOGO**: 252,528,000 US dollars
- **VIMIZIM**: 194,371,000 US dollars
- **NAGLAZYME**: 135,255,000 US dollars
- **PALYNZIQ**: 135,167,000 US dollars
- **GALAFOLD**: 105,748,000 US dollars
- **BRINEURA**: 51,370,000 US dollars
- **ALDURAZYME**: 43,539,000 US dollars
- **POMBILITI + OPFOLDA**: 30,258,000 US dollars
- **KUVAN**: 24,444,000 US dollars
- **ROCTAVIAN**: 11,713,000 US dollars
- **Selling, general and administrative**: 395,549,000 US dollars
- **Research and development**: 206,952,000 US dollars
- **Intangible asset amortization**: 73,492,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2)

- Page: https://plicit.ai/financials/bmrn/fy2026-q2-income-statement/revenue-by-product-and-service-2
- Chart image: https://plicit.ai/charts/bmrn-fy2026-q2-revenue-by-product-and-service-2-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (SEGMENT INFORMATION- Schedule of Disaggregation of Total Net Product Revenues by Geographic Region). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 989,708,000 US dollars
- **Cost of sales**: 202,795,000 US dollars
- **Gross profit (calculated)**: 786,913,000 US dollars
- **Operating expenses (calculated)**: 675,993,000 US dollars
- **INCOME FROM OPERATIONS**: 110,920,000 US dollars
- **Other income (expense), net (calculated)**: negative 49,536,000 US dollars
- **INCOME BEFORE INCOME TAXES**: 61,384,000 US dollars
- **Provision for income taxes**: 16,622,000 US dollars
- **NET INCOME**: 44,762,000 US dollars
- **ALDURAZYME**: 43,539,000 US dollars
- **Net product revenues**: 984,393,000 US dollars
- **Selling, general and administrative**: 395,549,000 US dollars
- **Research and development**: 206,952,000 US dollars
- **Intangible asset amortization**: 73,492,000 US dollars
- **Revenue before reconciliation (calculated)**: 1,027,932,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 38,224,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service by Sales Channel

- Page: https://plicit.ai/financials/bmrn/fy2026-q2-income-statement/revenue-by-product-and-service-by-sales-channel
- Chart image: https://plicit.ai/charts/bmrn-fy2026-q2-revenue-by-product-and-service-by-sales-channel-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and Service by Contract with Customer, Sales Channel. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 989,708,000 US dollars
- **Cost of sales**: 202,795,000 US dollars
- **Gross profit (calculated)**: 786,913,000 US dollars
- **Operating expenses (calculated)**: 675,993,000 US dollars
- **INCOME FROM OPERATIONS**: 110,920,000 US dollars
- **Other income (expense), net (calculated)**: negative 49,536,000 US dollars
- **INCOME BEFORE INCOME TAXES**: 61,384,000 US dollars
- **Provision for income taxes**: 16,622,000 US dollars
- **NET INCOME**: 44,762,000 US dollars
- **Royalty and other revenues**: 5,315,000 US dollars
- **ALDURAZYME - Marketed by Sanofi**: 43,539,000 US dollars
- **Products excluding ALDURAZYME - Marketed by Company**: 940,854,000 US dollars
- **Selling, general and administrative**: 395,549,000 US dollars
- **Research and development**: 206,952,000 US dollars
- **Intangible asset amortization**: 73,492,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (3)

- Page: https://plicit.ai/financials/bmrn/fy2026-q2-income-statement/revenue-by-product-and-service-3
- Chart image: https://plicit.ai/charts/bmrn-fy2026-q2-revenue-by-product-and-service-3-sankey.png

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 989,708,000 US dollars
- **Cost of sales**: 202,795,000 US dollars
- **Gross profit (calculated)**: 786,913,000 US dollars
- **Operating expenses (calculated)**: 675,993,000 US dollars
- **INCOME FROM OPERATIONS**: 110,920,000 US dollars
- **Other income (expense), net (calculated)**: negative 49,536,000 US dollars
- **INCOME BEFORE INCOME TAXES**: 61,384,000 US dollars
- **Provision for income taxes**: 16,622,000 US dollars
- **NET INCOME**: 44,762,000 US dollars
- **Net product revenues**: 984,393,000 US dollars
- **Royalty and other revenues**: 5,315,000 US dollars
- **Selling, general and administrative**: 395,549,000 US dollars
- **Research and development**: 206,952,000 US dollars
- **Intangible asset amortization**: 73,492,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.